Literature DB >> 27635948

SMARCB1/INI1 Involvement in Pediatric Chordoma: A Mutational and Immunohistochemical Analysis.

Manila Antonelli1, Alessandro Raso, Samantha Mascelli, Marco Gessi, Paolo Nozza, Antonella Coli, Marina P Gardiman, Antonietta Arcella, Maura Massimino, Francesca R Buttarelli, Felice Giangaspero.   

Abstract

Chordomas arise in the skull base and spine and usually occur in adults and are rare in the pediatric population. Cases of chordoma in pediatric age are often poorly differentiated, showing cytologic atypia, increased cellularity, and mitosis, and their aggressive behavior is associated with a high incidence of metastatic spread and a short patient survival. Recent studies have described loss of SMARCB1/INI1 protein in poorly differentiated chordomas associated not with point mutations but with SMARCB1/INI1 gene deletions instead. In this study, we considered immunohistochemistry and SMARCB1/INI1 mutational status to examine SMARCB1 status in a series of pediatric chordomas (7 classic and 1 poorly differentiated). We performed immunohistochemical tests for INI1, brachyury, S100, and cytokeratins and conducted a genetic analysis on the SMARCB1 coding sequence (NM_003073) using the Sanger method and multiplex ligation-dependent probe amplification to detect abnormal copy numbers of the gene locus. All 8 cases were positive for brachyury, whereas there was no nuclear SMARCB1/INI1 expression in 4 of the 8 cases, including the poorly differentiated chordoma. Genetic analysis identified a missense mutation in 2 cases and a nonsense mutation associated with loss of SMARCB1/INI1 protein and features of poorly differentiated tumor in 1. These mutations were novel variants occurring in heterozygosity, and they were judged to be pathogenic by 3 different bioinformatic tools. In 7 of 8 cases we performed multiplex ligation-dependent probe amplification, and 3 cases showed deletions at the SMARCB1 locus. Our results confirm the pathogenic involvement of SMARCB1/INI1 in childhood chordoma. We also describe 3 novel pathogenic mutations.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27635948     DOI: 10.1097/PAS.0000000000000741

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  13 in total

Review 1.  Soft Tissue Special Issue: Chondroid Neoplasms of the Skull.

Authors:  A N Flaman; J K Wasserman; D H Gravel; B M Purgina
Journal:  Head Neck Pathol       Date:  2020-01-16

2.  SNF5 as a prognostic factor in skull base chordoma.

Authors:  Mingxuan Li; Yixuan Zhai; Jiwei Bai; Shuai Wang; Hua Gao; Chuzhong Li; Songbai Gui; Jiang Du; Yazhuo Zhang
Journal:  J Neurooncol       Date:  2017-12-08       Impact factor: 4.130

3.  Chordoma Occurs in Young Children With Tuberous Sclerosis.

Authors:  Nathan A Dahl; Timothy Luebbert; Michele Loi; Ilana Neuberger; Michael H Handler; Bette Kay Kleinschmidt-DeMasters; Jean M Mulcahy Levy
Journal:  J Neuropathol Exp Neurol       Date:  2017-06-01       Impact factor: 3.685

4.  Unusual extradural chordoma in an adolescent presenting with lumbar radiculopathy.

Authors:  Lianne Chau; Denise M Malicki; Michael L Levy; John Ross Crawford
Journal:  BMJ Case Rep       Date:  2020-04-06

Review 5.  Oncogenic roles of SMARCB1/INI1 and its deficient tumors.

Authors:  Kenichi Kohashi; Yoshinao Oda
Journal:  Cancer Sci       Date:  2017-04-12       Impact factor: 6.716

6.  Clinicopathological and Prognostic Characteristics in Dedifferentiated/Poorly Differentiated Chordomas: A Pooled Analysis of Individual Patient Data From 58 Studies and Comparison With Conventional Chordomas.

Authors:  Fu-Sheng Liu; Bo-Wen Zheng; Tao-Lan Zhang; Jing Li; Guo-Hua Lv; Yi-Guo Yan; Wei Huang; Ming-Xiang Zou
Journal:  Front Oncol       Date:  2021-08-13       Impact factor: 6.244

7.  Clinical response to nivolumab in an INI1-deficient pediatric chordoma correlates with immunogenic recognition of brachyury.

Authors:  Laura M Williamson; Craig M Rive; Daniela Di Francesco; Emma Titmuss; Hye-Jung E Chun; Scott D Brown; Katy Milne; Erin Pleasance; Anna F Lee; Stephen Yip; Daniel G Rosenbaum; Martin Hasselblatt; Pascal D Johann; Marcel Kool; Melissa Harvey; David Dix; Daniel J Renouf; Robert A Holt; Brad H Nelson; Martin Hirst; Steven J M Jones; Janessa Laskin; Shahrad R Rassekh; Rebecca J Deyell; Marco A Marra
Journal:  NPJ Precis Oncol       Date:  2021-12-20

8.  Poorly differentiated chordoma with whole-genome doubling evolving from a SMARCB1-deficient conventional chordoma: A case report.

Authors:  Christian Curcio; Robert Cimera; Ruth Aryeequaye; Mamta Rao; Nicola Fabbri; Yanming Zhang; Meera Hameed
Journal:  Genes Chromosomes Cancer       Date:  2020-10-07       Impact factor: 5.006

Review 9.  Immunotherapy for Chordoma and Chondrosarcoma: Current Evidence.

Authors:  Jeffrey I Traylor; Mark N Pernik; Aaron R Plitt; Michael Lim; Tomas Garzon-Muvdi
Journal:  Cancers (Basel)       Date:  2021-05-17       Impact factor: 6.639

10.  Chordoma: A Case Report and Review of Literature.

Authors:  Arish Noor; Poorva Bindal; Miguel Ramirez; James Vredenburgh
Journal:  Am J Case Rep       Date:  2020-01-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.